Volume 6, Issue 1 (6-2019)                   vacres 2019, 6(1): 13-24 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kiseleva I, Stepanova E, Krutikova E, Donina S, Rekstin A, Bazhenova E, et al . Could Trivalent LAIV Protect Against Both Genetic Lineages of Influenza B Virus?. vacres. 2019; 6 (1) :13-24
URL: http://vacres.pasteur.ac.ir/article-1-163-en.html
Institute of Experimental Medicine
Abstract:   (2566 Views)
Introduction: The global co-circulation of two influenza B virus genetic lineages known as B/Yamagata and B/Victoria may lead to a mismatch between the circulating virus and the strain recommended for use in influenza vaccines. Little is known about the protective efficacy of unmatched influenza B strains, especially when it comes to live attenuated influenza vaccine. The main purpose of this study was to demonstrate the viability of using live attenuated influenza vaccine developed on B/USSR/60/69 backbone to protect from heterologous influenza B challenge infection.
Methods: To estimate the potential cross-protective activity of mono- and trivalent live attenuated vaccines based on B/Victoria or B/Yamagata genetic lineage virus against a heterological challenge. Ferrets were given one dose of vaccine and then challenged with influenza B virus and monitored for clinical signs associated with influenza infection. Samples of the ferrets’ airways were tested for the presence of challenge virus.
Results: Mono- and trivalent live attenuated influenza vaccines were shown to be safe and cross-protective against genetically different influenza B viruses based on virological and histological data and clinical signs. A lower titer of heterologous challenge virus in the airways of vaccinated ferrets compared to mock-vaccinated animals inoculated with challenge virus was detected. Interestingly, B/Victoria-based vaccines were more cross-protective compared with B/Yamagata-based vaccines.
Conclusion: In the case of mismatches of B component of the trivalent live attenuated influenza vaccine and lineage of the circulating influenza B viruses, one of the options could be using trivalent preparation containing a B/Victoria lineage component.
Full-Text [PDF 1316 kb]   (674 Downloads)    
Type of Study: Research | Subject: Vaccine development, efficacy and safety evaluation
Received: 2020/01/3 | Accepted: 2020/02/26 | Published: 2020/04/13

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.